Abstract: The present invention provides a polynucleotide (ipkc) which identifies and encodes a novel human protein kinase C inhibitor homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC. The invention also provides for the use of purified IPKC and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of IPKC. Additionally, the invention provides for the use of antisense molecules to ipkc in pharmaceutical compositions for treatment of diseases associated with the expression of IPKC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ipkc. The present invention also relates to anti-IPKC antibodies which specifically bind to IPKC.

Abstract: The present invention provides polynucleotides which identify and encode a novel human nm23-like protein (H-nm23). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding H-nm23 and for a method for producing the protein. The invention also provides for the use of substantially purified H-nm23 for the treatment of diseases associated with the expression of H-nm23. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding H-nm23 and antibodies which specifically bind to the protein.

Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human galectin-8. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding human galectin-8. The invention also provides for the production and use of substantially purified human galectin-8 in pharmaceutical compositions to increase immune responses. The invention also provides for the use of antisense molecules and antibodies in pharmaceutical compositions to decrease immune response. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts and/or genomic DNA encoding human galectin-8 and anti-human galectin-8 antibodies which specifically bind to human galectin-8.

Abstract: The present invention provides novel human protein kinases (HPK) and polynucleotides which identify and encode HPK. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPK. The invention also provides for pharmaceutical compositions comprising HPK or antagonists of HPK, and antibodies which specifically bind HPK. Additionally, the invention provides antisense molecules to HPK for treatment or prevention of diseases associated with abnormal expression of HPK.

Abstract: The present invention provides a human squalene epoxidase (HSQEP) and polynucleotides which identify and encode HSQEP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSQEP and a method for producing HSQEP. The invention also provides for the use of HSQEP and agonists, antibodies, or antagonists specifically binding HSQEP, in the prevention and treatment of diseases associated with expression of HSQEP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSQEP for the treatment of diseases associated with the expression of HSQEP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSQEP.

Abstract: The present invention provides polynucleotides which identify and encode a novel human nucleic acid binding protein (NABP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NABP. The invention also provides for the use of substantially purified NABP or its antagonists, in pharmaceutical compositions for the treatment of diseases associated with the expression of NABP. Additionally, the invention provides for the use of antisense molecules to NABP in pharmaceutical compositions for treatment of diseases associated with the expression of NABP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding NABP or anti-NABP antibodies which specifically bind to NABP.

Abstract: The present invention provides a polynucleotide (hhp) which identifies and encodes a novel human hyaluronidase (HHP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HHP. The invention also provides for the use of substantially purified HHP and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of HHP. Additionally, the invention provides for the use of antisense molecules to hhp in pharmaceutical compositions for treatment of diseases associated with the expression of HHP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of hhp. The present invention also relates to anti-HHP antibodies which specifically bind to HHP.

Abstract: The present invention provides a polynucleotide (snpg) initially isolated from a colon cDNA library which identifies and encodes a novel human synaptogyrin homolog (SNPG). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding SNPG. The invention also provides for the use of SNPG in the membrane of a vesicle containing a chemical or biological therapeutic composition for the treatment of disease, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the abnormal or excess expression of SNPG. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of snpg, or anti-SNPG antibodies which specifically bind to the polypeptide, SNPG.

Abstract: The present invention provides nucleic acid and amino acid sequences that identify and encode a novel human map kinase homolog (SMAP) expressed in cells of the human stomach. The present invention also provides for PCR oligomers or hybridization probes for the detection of nucleotide sequences encoding SMAP or SMAP-like molecules, antisense molecules to the nucleotide sequences which encode SMAP, diagnostic tests based on SMAP encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified SMAP, antibodies capable of binding specifically to SMAP, and agonists and inhibitors with specific binding activity for the polypeptide SMAP.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel cellubrevin (CB). The present invention also provides for antisense molecules to the nucleotide sequences which encode CB, expression vectors for the production of purified CB, antibodies capable of binding specifically to CB, hybridization probes or oligonucleotides for detecting the upregulation of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CB, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CB.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, expression vectors for the production of purified ADEC, antibodies capable of binding specifically to ADEC, hybridization probes or oligonucleotides for the detection of ADEC-encoding nucleotide sequences, genetically engineered host cells for the expression of ADEC, diagnostic tests for inflammation or disease based on ADEC-encoding nucleic acid molecules or antibodies capable of binding specifically to ADEC.

Abstract: The present invention provides a human pyrophosphatase (HPYP) and polynucleotides which identify and encode HPYP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPYP and a method for producing HPYP. The invention also provides for use of HPYP and agonists, antibodies, or antagonists specifically binding HPYP, in the prevention and treatment of cancer and inflammatory diseases. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPYP for the treatment of diseases associated with the expression of HPYP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPYP.

Abstract: The present invention provides a polynucleotide PTEC (prostate expressed chemokine) isolated from a prostate cDNA library which identifies and encodes a novel human rantes homolog PTEC (prostate expressed chemokine). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PTEC. The invention also provides for the therapeutic use of purified PTEC in the treatment of immune deficiency diseases, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the expression of PTEC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.

Abstract: The present invention provides three novel GTP-binding proteins (designated individually as BND-1, BND-2, and BND-3, and collectively as BND) and polynucleotides which identify and encode BND. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding BND and a method for producing BND. The invention also provides for use of BND and agonists, antibodies, or antagonists specifically binding BND, in the prevention and treatment of diseases associated with expression of BND. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding BND for the treatment of diseases associated with the expression of BND. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding BND.

Abstract: The present invention provides two novel human galectins (designated individually as GAL-5HA and GAL-5HB, and collectively as GAL-5H) and polynucleotides which identify and encode GAL-5H. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding GAL-5H and a method for producing GAL-5H. The invention also provides for use of GAL-5H and agonists, antibodies, or antagonists specifically binding GAL-5H, in the prevention and treatment of diseases associated with expression of GAL-5H. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding GAL-5H for the treatment of diseases associated with the expression of GAL-5H. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding GAL-5H.

Abstract: The present invention provides polynucleotides which identify and encode a novel human glycoprotein (SC2H). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding SC2H. The invention also provides for the use of substantially purified SC2H and its agonists in the commercial production of recombinant proteins for the treatment of diseases associated with the expression of SC2H. Additionally, the invention provides for the use of antisense molecules to SC2H in the treatment of diseases associated with the expression of SC2H. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding SC2H and antibodies which specifically bind to the protein.

Abstract: The present invention provides polynucleotides (kin) which identify and encode novel protein kinases (KIN) expressed in various human cells and tissues. The present invention also provides for antisense sequences and oligonucleotides designed from the nucleotide sequences or their complements. The invention further provides genetically engineered expression vectors and host cells for the production of purified KIN peptides, antibodies capable of binding KIN, and inhibitors specifically bind KIN. The invention specifically provides for diagnostic kits and assays which identify a disorder or disease with altered kinase expression and allow monitoring of patients during drug therapy. These assays utilize oligonucleotides or antibodies produced using the kin polynucleotides.

Abstract: The invention provides human nucleotide kinases and polynucleotides which identify and encode DRNK. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DRNK.

Abstract: The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease.

Abstract: The present invention provides a novel human interferon-inducible protein (HIFI) and the polynucleotides which identify and encode HIFI. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HIFI and for a method for producing the protein. The invention also provides compositions containing HIFI.